Figures and Tables

From the following article:

Modelling Myc inhibition as a cancer therapy

Laura Soucek, Jonathan Whitfield, Carla P. Martins, Andrew J. Finch, Daniel J. Murphy, Nicole M. Sodir, Anthony N. Karnezis, Lamorna Brown Swigart, Sergio Nasi & Gerard I. Evan

Nature 455, 679-683(2 October 2008)

doi:10.1038/nature07260

BACK TO ARTICLE
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 1

Endogenous Myc function is required for formation and maintenance of early-stage Kras-induced lung hyperplasias/adenomas.

Full size figure and legend (745K)Download PowerPoint slide (1,128K)
Figure 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 2

Myc inhibition elicits regression of established lung tumours.

Full size figure and legend (723K)Download PowerPoint slide (1,107K)
Figure 3 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 3

Inhibition of endogenous Myc suppresses proliferation in skin, testis and GI tract.

Full size figure and legend (741K)Download PowerPoint slide (1,124K)
Figure 4 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 4

The degenerative phenotypes induced by systemic Myc inhibition are rapidly and completely reversible on restoration of Myc function.

Full size figure and legend (599K)Download PowerPoint slide (982K)

Slides may be downloaded for educational use, according to the terms described in Nature Publishing Group's licensing policy.

BACK TO ARTICLE